Explore FOXO4-DRI dosage trends, reconstitution volumes, and vial size patterns from anonymized WPA peptide calculator data.
FOXO4-DRI is a 26-residue D-retro-inverso peptide studied as a proof-of-concept senolytic (a compound that targets senescent cells) in aging research. It ships as a lyophilized powder you reconstitute before use, so the meaningful vendor difference is what the certificate of analysis (COA) shows.
In senescent cells, FOXO4 binds p53 in the nucleus and keeps it sequestered, preventing the cell from undergoing the apoptosis it would otherwise be primed for. FOXO4-DRI competitively disrupts the FOXO4–p53 interaction, releasing p53 to translocate to mitochondria and trigger intrinsic apoptosis — selectively in senescent cells, because only they have the elevated FOXO4 that creates the dependency.[1] The D-retro-inverso design (D-amino acids in reversed sequence) is intended to maintain conformational mimicry of the native L-peptide while resisting proteolytic degradation, extending in-vivo half-life.
Baar et al. (Cell 2017) reported that intraperitoneal FOXO4-DRI in aged mice reduced markers of cellular senescence, restored fitness and hair-coat density, and improved renal function — among the most striking aging-phenotype-reversal results in the senolytic literature.[1] Subsequent work has explored FOXO4-DRI in idiopathic pulmonary fibrosis models and chemotherapy-induced senescence.[2][3] No human clinical trial of FOXO4-DRI has been registered or conducted.[4]
Not FDA-approved. No registered human clinical trial. Pre-clinical mouse data only. Research-grade material for non-clinical use.
FOXO4-DRI has a reported half-life of ~few hours (estimated). The pharmacokinetic reference models an interval of intermittent (senolytic pulses); this is not a measured community cadence or a dosing recommendation. A short-acting senolytic peptide given in spaced pulses rather than continuously, so each dose clears well before the next with no buildup. Pharmacokinetic source: Pre-clinical only; senolytic peptide (Baar et al. Cell 2017). It is catalogued under Anti-Aging Peptides on WPA.
62 FOXO4-DRI reconstitution calculations have been logged by the WPA community.
This is the lifetime header population. Each chart and its associated analysis below use their own selected period and denominator; frequency responses are a separate cohort.
These figures come from anonymized WPA peptide calculator sessions, not verified administrations or unique people. Separate modal inputs do not establish a joint protocol. They are community input statistics — not dosing recommendations, and not medical advice.
These figures come from anonymized WPA peptide calculator sessions.
All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.